Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Kona SUV: The Courageous Minimized That is Catching Hearts Around the world - 2Bolsonaro briefly leaves Brazilian prison for medical tests after a fall from his bed
- 3Extraordinary Snowboarding Objections All over the Planet
- 4Which game do you cherish observing live? Vote!
- 5A NASA spacecraft orbiting Mars may be dead
- Private sector revives the climate disaster database Trump tried to squash
- Astronomers discover never-before-seen celestial object: "Cloud 9"
- What is IDF's view on pontential long-term occupation of southern Lebanon?
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- A hunger for new experiences Narratives: Motivating Travel and Experience
- Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
